Eesti - eesti - Ravimiamet

novartis baltics sia - deksametasoon+neomütsiin+polümüksiin b - silmatilgad, suspensioon - 1mg+3500rÜ+6000rÜ 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

glaxo wellcome uk limited trading as glaxo wellcome operations - beetametasoon+neomütsiin - kreem - 1mg+5mg 1g 15g 1tk

Eesti - eesti - Ravimiamet

sandoz gmbh - batsitratsiin+neomütsiin - salv - 250rÜ+5000rÜ 1g 20g 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibacterials süsteemseks kasutamiseks, - Ägeda bakteriaalse naha ja naha struktuuri nakkuste (absssi) ravi täiskasvanutel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).